Acute cardiac care & resuscitation

Early Post-ROSC Laboratory Phenotypes and Clinical Outcomes after Out-of-Hospital Cardiac Arrest: A 10-Year National Cohort Study

ResuscitationPublished retrospective cohort study

Authors' conclusion

Early post-ROSC laboratory data identified three prognostically distinct phenotypes among resuscitated OHCA patients. These exploratory findings support external validation and investigation of phenotype-guided therapies.

Study context

Population
Adult resuscitated out-of-hospital cardiac arrest (OHCA) patients of presumed cardiac etiology in Singapore, 2011–2022
Participants
1,514 eligible patients
Exposure
Homeostatic (HOM) and immune-dysregulated (IMD) phenotypes compared to multi-organ dysfunction (MOD)
  • MODn = 286reference
  • HOMn = 967
  • IMDn = 261
Methodological detailsunsupervised latent class analysis, split-sample validation, national databases
  • Unsupervised latent class analysis
  • Split-sample validation
  • National databases

Main finding

As reported in the abstract

Poor neurological recovery · hospital discharge
Each group vs MODAdjusted odds ratio (95% CI)P value
HOM
0.50(0.30–0.78)
P = 0.004
IMD
0.46(0.26–0.78)
P = 0.005

Observational data: associations, not effects.

Further findings

OutcomeaHR (95% CI)P value
30-day mortality · 30 days — HOM vs MOD0.71 (0.61–0.83)P ≤ 0.01
30-day mortality · 30 days — IMD vs MOD0.78 (0.64–0.94)P ≤ 0.01
3-year mortality · 3 years — HOM vs MOD0.70 (0.60–0.82)P ≤ 0.01
3-year mortality · 3 years — IMD vs MOD0.74 (0.62–0.90)P ≤ 0.01

Phenotype reproducibility

Derivation entropy
0.817
Replication entropy
0.892
Most discriminative variables: creatinine, eosinophil and lymphocyte

Original publication

Early Post-ROSC Laboratory Phenotypes and Clinical Outcomes after Out-of-Hospital Cardiac Arrest: A 10-Year National Cohort Study. Resuscitation. Published 9 October 2026. doi:10.1016/j.resuscitation.2026.111351

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.